crizotinib

Interviews and expert commentary tagged “crizotinib” — the latest oncology research and clinical practice from the Audio Journal of Oncology.

ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 
Audio Journal of Oncology

ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 

MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK ge

7 November 2018
9 minutes
Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib
Audio Journal of Oncology

Second-Generation ALK Inhibitor = Longer PFS in ALK+ Lung Cancer After Crizotinib

COPENHAGEN—Longer progression free survival (PFS) was achieved in patients with ALK-rearranged non-small cell lung cancer (NSCLC) previously treated with crizotinib randomised to treatment with the se

8 December 2016
8:52 secs